New Risk • Mar 27
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩9.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩9.6b free cash flow). Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩135.1b market cap, or US$89.4m). Annuncio • Feb 28
T&R Biofab Co., Ltd., Annual General Meeting, Mar 26, 2026 T&R Biofab Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 237, sangidaehak-ro, gyeonggi-do, siheung South Korea New Risk • Feb 19
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩144.1b (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩144.1b market cap, or US$99.5m). Reported Earnings • Dec 05
Third quarter 2025 earnings released Third quarter 2025 results: ₩265 loss per share. Net loss: ₩5.71b (flat on 3Q 2024). New Risk • Nov 23
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 74% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (74% increase in shares outstanding). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩63.5b market cap, or US$43.2m). New Risk • Oct 29
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₩10.1b (US$7.05m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (₩10.1b market cap, or US$7.05m). Minor Risk Less than 3 years of financial data is available. Annuncio • Oct 22
T&R Biofab Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 22.664029 billion. T&R Biofab Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 22.664029 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 15,904,582
Price\Range: KRW 1425
Discount Per Security: KRW 28.5
Transaction Features: Rights Offering New Risk • Sep 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩47.7b market cap, or US$34.5m). New Risk • Apr 23
New minor risk - Financial data availability Less than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue has declined by 6.3% over the past year. Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (₩4.9b revenue, or US$3.4m). Market cap is less than US$100m (₩112.7b market cap, or US$79.1m). Annuncio • Mar 12
T&R Biofab Co., Ltd., Annual General Meeting, Mar 25, 2025 T&R Biofab Co., Ltd., Annual General Meeting, Mar 25, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 237, sangidaehak-ro, gyeonggi-do, siheung South Korea New Risk • Mar 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Revenue is less than US$5m (₩5.1b revenue, or US$3.5m). Market cap is less than US$100m (₩67.8b market cap, or US$46.4m). New Risk • Dec 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Revenue is less than US$5m (₩5.1b revenue, or US$3.4m). Market cap is less than US$100m (₩93.4b market cap, or US$63.4m). New Risk • Nov 12
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩131.9b (US$93.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩4.9b revenue, or US$3.5m). Market cap is less than US$100m (₩131.9b market cap, or US$93.8m). Annuncio • Aug 06
T&R Biofab Co., Ltd. announced that it has received KRW 7 billion in funding from BTC Investment On August 5, 2024, T&R Biofab Co., Ltd. closed the transaction. New Risk • Jun 14
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩138.1b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩4.8b revenue, or US$3.5m). Market cap is less than US$100m (₩138.1b market cap, or US$99.9m). New Risk • Jan 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 39% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$5m (₩4.9b revenue, or US$3.7m). Annuncio • Dec 22
T&R Biofab Co., Ltd. announced that it has received KRW 1.999996 billion in funding from Korea Investment Partners Co. Ltd., DreamCIS, Inc. On December 22, 2023, T&R Biofab Co., Ltd. closed the transaction. Annuncio • Aug 05
T&R Biofab Co., Ltd. announced that it has received KRW 24 billion in funding On August 4, 2023, T&R Biofab Co., Ltd. closed the transaction. Annuncio • Aug 08
T&R Biofab Co., Ltd. announced that it has received KRW 35 billion in funding from a group of investors On August 6, 2021, T&R Biofab Co., Ltd. (KOSDAQ:A246710) closed the transaction. Is New 90 Day High Low • Mar 09
New 90-day high: ₩19,550 The company is up 8.0% from its price of ₩18,150 on 09 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 5.0% over the same period. Is New 90 Day High Low • Nov 23
New 90-day high: ₩18,900 The company is up 40% from its price of ₩13,500 on 26 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 4.0% over the same period. Is New 90 Day High Low • Oct 27
New 90-day low: ₩11,500 The company is down 14% from its price of ₩13,300 on 29 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 5.0% over the same period. Annuncio • Oct 10
T&R Biofab Co., Ltd. announced that it has received KRW 13.99997475 billion in funding from Korea Investment Partners Co. Ltd., eBest Investment Securities Co., Ltd., Investment Arm On October 8, 2020, T&R Biofab Co., Ltd. (KOSDAQ:A246710) closed the transaction. Annuncio • Sep 30
T&R Biofab Co., Ltd. announced that it expects to receive KRW 13.99997475 billion in funding from Korea Investment Partners Co. Ltd., eBest Investment Securities Co., Ltd., Investment Arm and other investors T&R Biofab Co., Ltd. (KOSDAQ:A246710) announced a private placement of 1,072,795 registered convertible preferred shares of face value KRW 500 at a price of KRW 13,050 for gross proceeds of KRW 13,999,974,750 on September 29, 2020. The transaction will include participation from new investors Korea Investment Bio-Global Fund, a fund managed by Korea Investment Partners Co. Ltd. for 766,283 preferred shares, eBest Investment Securities Co., Ltd., Investment Arm for 76,628 preferred shares, Jaedam Co., Ltd. for 153,256 preferred shares and BTCI No. 1 2018 Private Equity Partnership for 76,628 preferred shares. The preferred shares are non-cumulative, non-participating, bear an interest of 1% per annum and mature in 5 years from the date of issue. The preferred stock is convertible into one registered common share at a conversion price of KRW 13,050 from October 13, 2021 to October 12, 2025. The transaction has been approved by board of directors of the company. The company is issuing shares through a third party allotment at a premium and the shares are subject to a lock-up period of one year from the date of issuance. The transaction is expected to close on October 12, 2020.
On the same date, the company amended the terms of the transaction. The company will now issue 919,535 shares for gross proceeds of KRW 11,999,931,750 in the transaction. 
